Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds
With Neuron23, Westlake Unveils Second Start-Up In A Week
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
You may also be interested in...
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.